Preclinical studies have highlighted isatuximab's ability to induce Fc-dependent mechanisms such as ADCC, ADCP, and CDC (14, 20–22); Fc-independent mechanisms, including the induction of direct cytotoxicity in tumor cells (31); and inhibition of CD38 enzymatic activities (14), as well as wider immunomodulatory effects (20). This evidence concerns the gene CD38 and neoplasm.